Qualigen Therapeutics, Inc.
QLGN
|
$0.301
-3.43%
-3.55%
30K
|
Health Technology
(0.0% 1d) (-13.0% 1m) (-67.0% 1y) (0.0% 2d) (6.7% 3d) (-1.8% 7d) (-35.61% volume)
Earnings Calendar: 2022-11-15
Market Cap: $ 1,898,519
http://www.qualigeninc.com
Sec Filling | Patents | 5 employees
(US) Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. The company's cancer therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F3 and STARS™. ALAN (AS1411-GNP) is a DNA coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer with minimal side effects. RAS-F3 is a small molecule RAS oncogene protein-protein inhibitor for blocking RAS mutations that lead to tumor formation, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA-based treatment device for removal from circulating blood of precisely targeted tumor-produced and viral compounds. The company is headquartered in Los Angeles, CA.
cancer lung cancer infectious disease lungs pancreatic treatment
add to watch list Paper trade email alert is off
Press-releases
Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™
Published: 2024-04-16 (Crawled : 11:00) - globenewswire.com
MRZM | $0.095 1031.22% 2.2K
|
Information
|
| O: 0.0%
H: 72.73%
C: 72.73%
QLGN | $0.301 -3.43% -3.55% 30K
|
Health Technology
|
| O: -4.91%
H: 3.23%
C: -3.29%
for commercialization therapeutics agreement
Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting
Published: 2024-04-10 (Crawled : 12:00) - globenewswire.com
QLGN | $0.301 -3.43% -3.55% 30K
|
Health Technology
|
| O: -2.03%
H: 2.35%
C: -2.76%
association direct cancer research meeting
Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting
Published: 2024-04-09 (Crawled : 12:00) - globenewswire.com
QLGN | $0.301 -3.43% -3.55% 30K
|
Health Technology
|
| O: 3.2%
H: 0.0%
C: -0.28%
qn-302 association positive cancer research meeting therapeutics
Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023
Published: 2023-11-14 (Crawled : 22:00) - globenewswire.com
QLGN | $0.301 -3.43% -3.55% 30K
|
Health Technology
|
| O: 4.76%
H: 0.0%
C: -4.55%
update therapeutics
Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors
Published: 2023-11-07 (Crawled : 14:00) - globenewswire.com
QLGN | $0.301 -3.43% -3.55% 30K
|
Health Technology
|
| O: 2.86%
H: 4.17%
C: 0.38%
qn-302 tumors treatment trial therapeutics
Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast Cancer
Published: 2023-10-23 (Crawled : 12:30) - globenewswire.com
QLGN | $0.301 -3.43% -3.55% 30K
|
Health Technology
|
| O: 1.65%
H: 0.0%
C: -6.23%
breast cancer platform
Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023
Published: 2023-09-27 (Crawled : 14:30) - biospace.com/
QLGN | $0.301 -3.43% -3.55% 30K
|
Health Technology
|
| O: 0.96%
H: 0.0%
C: -1.9%
qn-302 cancer pancreatic therapeutics
Qualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid Tumors
Published: 2023-08-17 (Crawled : 12:00) - globenewswire.com
QLGN | $0.301 -3.43% -3.55% 30K
|
Health Technology
|
| O: -0.94%
H: 0.0%
C: -1.83%
qn-302 tumors treatment therapeutics
Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023
Published: 2023-08-15 (Crawled : 12:20) - globenewswire.com
QLGN | $0.301 -3.43% -3.55% 30K
|
Health Technology
|
| O: -1.9%
H: 6.8%
C: 6.14%
update financial results
Qualigen Therapeutics Announces US FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors
Published: 2023-08-01 (Crawled : 12:00) - globenewswire.com
QLGN | $0.301 -3.43% -3.55% 30K
|
Health Technology
|
| O: 10.62%
H: 0.8%
C: -9.6%
qn-302 fda tumors treatment clearance trial therapeutics
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 67% | 33% |
Top 10 Gainers
Last 48 Hours Insiders Buying
RXO P 200000 | $19.37 2.32% 0.0% 1M
|
n/a
|
23:00
RKT P 380 | $11.68 1.3% 0.17% 1.9M
|
Finance
|
22:30
HROW P 29400 | $10.43 -3.87% -4.03% 680K
|
Health Technology
|
22:30
BCDA P 2750 | $0.377 -1.4% 97K
|
Health Technology
|
22:00
RMCF | $3.67 3.38% 3.27% 11K
|
Consumer Non-Durables
|
20:10